Milestone Pharmaceuticals INC Form 4 insider transactions

Milestone Pharmaceuticals Inc. Director Andrew Saik was granted 40,000 stock options with an exercise price of $1.75, vesting monthly over one year.

Milestone Pharmaceuticals Inc. director Lisa M. Giles was granted 40,000 stock options with an exercise price of $1.75, vesting monthly over one year or upon the next annual meeting.

Jeffrey Edward Nelson, Chief Operating Officer of Milestone Pharmaceuticals, received stock options and restricted stock units on January 27, 2025.

Amit Hasija, CFO & EVP of Corporate Development at Milestone Pharmaceuticals, received stock options and restricted stock units on January 27, 2025, according to a Form 4 filing.

Lorenz Muller, Chief Commercial Officer of Milestone Pharmaceuticals, received stock options for 120,600 shares and 80,400 restricted stock units on January 27, 2025.

Chief Medical Officer David Bharucha receives stock options and restricted stock units from Milestone Pharmaceuticals Inc.

CEO Joseph Oliveto reports acquisition of shares and stock options in Milestone Pharmaceuticals.

Director Joseph C. Papa acquired stock options for 80,000 common shares of Milestone Pharmaceuticals Inc. on September 3, 2024.

Director Andrew Saik of Milestone Pharmaceuticals Inc. was granted 40,000 stock options on August 28, 2024, according to a Form 4 filing with the SEC.

Lisa M. Giles, a director of Milestone Pharmaceuticals Inc., acquired stock options for 40,000 common shares on August 28, 2024.

Director Stuart Duty acquired 40,000 stock options in Milestone Pharmaceuticals, according to a recent SEC Form 4 filing.

Director Seth H. Z. Fischer acquired 40,000 stock options in Milestone Pharmaceuticals Inc. on August 28, 2024.

Director Michael John Tomsicek acquired 40,000 stock options in Milestone Pharmaceuticals Inc. on August 28, 2024.

Robert James Wills, a director of Milestone Pharmaceuticals Inc., acquired 40,000 stock options on August 28, 2024, according to a Form 4 filing with the SEC.

Director Andrew Saik of Milestone Pharmaceuticals Inc. was granted stock options to purchase 80,000 common shares on July 15, 2024.

Director Stuart Duty acquired stock options for 80,000 common shares in Milestone Pharmaceuticals, according to a recent SEC filing.